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The rhesus monkey intrinsic immunity factor TRIM5rh recognizes incoming capsids from a variety of
retroviruses, including human immunodeficiency virus type 1 (HIV-1) and equine infectious anemia virus
(EIAV), and inhibits the accumulation of viral reverse transcripts. However, direct interactions between
restricting TRIM5 proteins and retroviral capsids have not previously been demonstrated using pure recom-
binant proteins. To facilitate structural and mechanistic studies of retroviral restriction, we have developed
methods for expressing and purifying an active chimeric TRIM5rh protein containing the RING domain from
the related human TRIM21 protein. This recombinant TRIM5-21R protein was expressed in SF-21 insect cells
and purified through three chromatographic steps. Two distinct TRIM5-21R species were purified and shown
to correspond to monomers and dimers, as analyzed by analytical ultracentrifugation. Chemically cross-linked
recombinant TRIM5-21R dimers and mammalian-expressed TRIM5-21R and TRIM5 proteins exhibited
similar sodium dodecyl sulfate-polyacrylamide gel electrophoresis mobilities, indicating that mammalian
TRIM5 proteins are predominantly dimeric. Purified TRIM5-21R had ubiquitin ligase activity and could
autoubquitylate with different E2 ubiquitin conjugating enzymes in vitro. TRIM5-21R bound directly to
synthetic capsids composed of recombinant HIV-1 CA-NC proteins and to authentic EIAV core particles. HIV-1
CA-NC assemblies bound dimeric TRIM5-21R better than either monomeric TRIM5-21R or TRIM5-21R
constructs that lacked the SPRY domain or its V1 loop. Thus, our studies indicate that TRIM5 proteins are
dimeric ubiquitin E3 ligases that recognize retroviral capsids through direct interactions mediated by the
SPRY domain and demonstrate that these activities can be recapitulated in vitro using pure recombinant
proteins.
Susceptibility to retroviral infections influences species sur-
vival and has driven the evolution of cellular restriction factors
that inhibit retroviral replication. One important antiretroviral
intrinsic immune response is mediated by TRIM5, which can
block early postentry steps in the replication of certain retro-
viruses in specific primate lineages (3, 37, 55, 58). Under nor-
mal restrictive conditions, TRIM5 proteins block accumula-
tion of retroviral reverse transcripts (55) and accelerate the
rate at which viral capsids dissociate from high-molecular-
weight complexes into lower-molecular-weight subunits (42,
56). The allelic specificity of TRIM5 restriction is illustrated
by the fact that rhesus macaque TRIM5 potently inhibits
human immunodeficiency virus type 1 (HIV-1) replication,
whereas human TRIM5 instead exhibits restriction activity
against N-tropic murine leukemia virus but not HIV-1 (23, 29,
43, 55, 67). These differences can be attributed to the differ-
ential abilities of TRIM5 proteins to interact with retroviral
capsids after viral entry (34, 42, 56).
Like other tripartite (TRIM) family members, TRIM5 con-
tains RING, B-box, coiled-coil, and B30.2/SPRY domains, and
each of these domains contributes to restriction activity. The
RING domain of TRIM5 has intrinsic E3 ubiquitin ligase
activity (63, 64), which is important both for autoubiquitylation
and for protein turnover in vivo (12, 26). The E3 ubiquitin
ligase activity also contributes to restriction but is not abso-
lutely required (26, 41, 55), and the precise functions of ubiq-
uitylation and the role of the ubiquitin/proteasome system in
retroviral restriction are not yet fully understood. Specifically,
proteasome activity is not required for TRIM5 antiviral ac-
tivity per se (12, 41), but proteasome inhibitors do alter the
normal progression of TRIM5 restriction, allowing reverse
transcripts to accumulate and impairing the ability of TRIM5
to accelerate the dissociation of intact viral capsids (2, 10, 62).
Moreover, the restriction of incoming capsids results in pro-
teasome-dependent degradation of TRIM5 (47), again sug-
gesting possible involvement of the proteasome in the normal
stepwise progression of restriction.
The B-box domain of TRIM5 plays an essential, but still
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undefined role in restriction activity, and mutations in this
domain can influence protein turnover, intracellular localiza-
tion, and restriction activity (11). The coiled-coil and ensuing
linker 2 (L2) regions of TRIM5 also contribute to efficient
capsid binding and restriction, and these elements appear to
function primarily in protein oligomerization (27, 36). Cross-
linking studies have suggested that TRIM5 may function as a
trimer, but trimerization has not been rigorously demonstrated
by biophysical studies of pure TRIM5 proteins (36). Finally,
the C-terminal B30.2/SPRY domain of TRIM5 is essential
for viral capsid recognition and is the key determinant of an-
tiviral specificity (38, 41, 54–56, 68). Several motifs within the
SPRY domain have been subject to significant positive selec-
tion and exhibit pronounced variability between species (35,
38, 49, 50, 54, 57). In particular, variable region 1 (V1, residues
323 to 350 in rhesus TRIM5) is critical both for efficient
restriction and for capsid binding, and a single amino acid
alteration at position 332 of the V1 loop allows human
TRIM5 to bind HIV-1 capsids and inhibit HIV-1 replication
(34, 54, 68). These and other observations show that the SPRY
domain dictates retroviral capsid recognition, although direct
binding interactions have not yet been demonstrated and char-
acterized using pure TRIM5 proteins.
TRIM5 proteins appear to recognize the outer shell of the
retroviral core particle, which is called the capsid. Lentiviruses
such as HIV-1 and equine infectious anemia virus (EIAV)
have conical capsids composed of CA protein hexamers that
form hexagonal assemblies called fullerene cones (4, 19–21, 28,
32). Intact retroviral core particles can be isolated from mem-
brane-stripped retroviruses and purified by using sucrose-gra-
dient centrifugation, but these assemblies are rather unstable
and typically disassemble spontaneously in buffer (1, 17, 30, 46,
60). Structural and biochemical studies of the HIV-1 capsid
have therefore frequently used synthetic assemblies created
from pure recombinant CA proteins (20). The assemblies
formed by pure HIV-1 CA-NC proteins on DNA templates are
particularly stable and can be formed under near physiological
conditions (7, 21). These CA-NC/DNA assemblies are a mix-
ture of cylindrical and conical structures that recapitulate the
hexagonal lattice of CA hexamers found in authentic viral
capsids (4, 21, 32). Synthetic HIV-1 CA-NC/DNA assemblies,
like membrane-stripped viral capsids, also bind exogenously
expressed TRIM5 proteins present in crude cell lysates (51,
56), indicating that the CA-NC/DNA assemblies recapitulate
the key elements required for TRIM5 recognition.
In summary, it is now well established that capsid recogni-
tion dictates the allelic specificity of TRIM5 restriction. How-
ever, direct interactions between pure TRIM5 proteins and
retroviral capsids have not yet been demonstrated in vitro,
largely owing to the technical challenges of creating suitable
capsid targets and of expressing and purifying recombinant
TRIM5 proteins. To date, soluble full-length TRIM5 pro-
teins have not been expressed successfully in Escherichia coli,
and TRIM5 proteins tend to turnover rapidly and aggregate
into cytoplasmic bodies when overexpressed in mammalian
systems (6, 12, 53). However, replacing the TRIM5 RING
domain with the RING domain from the homologous TRIM21
protein reduces protein turnover without compromising HIV-1
restriction substantially (12, 33). We have taken advantage of
this observation to develop systems for expressing and purify-
ing chimeric TRIM5-21R proteins in quantities suitable for
biochemical and biophysical characterization.
MATERIALS AND METHODS
Cell cultures. Human 293T and HeLa cells were maintained in Dulbecco
modified Eagle medium supplemented with 10% fetal calf serum. HeLa cells
stably expressing rhesus TRIM5 (TRIM5rh) (55) were maintained with an
additional supplement of 1 g of puromycin/ml.
Expression vectors. The pLPCX TRIM5-21R expression vector, encoding a
hemagglutinin (HA)-tagged TRIM5-21R (12), was used as a PCR template to
create a DNA fragment containing the TRIM5-21R gene with KpnI and XhoI
restriction sites. This fragment was ligated into the pCAG.OSFT (WISP-08-189)
backbone, which itself was modified from the pCAG vector backbone (Addgene)
to encode an N-terminal OneStrep and Flag (OSF) epitope tag followed by a
TEV protease cleavage site. The resulting vector, pCAG.OSFT-TRIM5-21R
(WISP-08-176), was used as a PCR template to amplify a DNA fragment with
terminal attB sites to allow for recombination into the pDONR221 Gateway
Entry Vector (Invitrogen) to create the pDONR221.OSFT-TRIM5-21R Entry
Vector (WISP-08-177). This vector was used as a template for QuikChange
site-directed mutagenesis (Stratagene) to create pDONR221.OSFT-TRIM5-
21RV1 (WISP-08-178) (deletion in the V1 variable loop of the SPRY domain
corresponding to TRIM5rh residues 332 to 344) and pDONR221.OSFT-
TRIM5-21RSPRY (WISP-08-179) (deletion of the entire SPRY domain and
L2 element, TRIM5rh residues 233 to 497). The pCAG.OSFT-TRIM5rh and
pDONR221.OSFT-TRIM5rh vectors (WISP-08-197 and -08-198) were con-
structed in an analogous fashion. Recombinant baculoviruses expressing TRIM5-
21R, TRIM5-21RV1, and TRIM5-21RSPRY were prepared in situ by using
the BaculoDirect system (Invitrogen). Equivalent mammalian cell expression
constructs were generated in the Gateway pcDNA-DEST40 vector (WISP-08-
180, -181, -182, and -199, respectively). pET28-based plasmids for bacterial
expression of UbcH5 (WISP-08-190), UbcH6 (WISP-08-191), UbcH7 (WISP08-
192), and Uba1 (WISP-08-192) were generous gifts from Rachel Klevit (Univer-
sity of Washington) (5, 8), and the Uba1 gene was originally a gift from Richard
Vierstra (University of Wisconsin) (22).
Expression and purification of recombinant proteins. (i) TRIM5-21R. Two
liters of SF-21 insect cells were grown to a density of 2  106 cells/ml in SF-900
II media (Invitrogen), infected at a multiplicity of infection of 1.0 with recom-
binant baculoviruses encoding TRIM5-21R and variants, and the expressed pro-
teins were allowed to accumulate for 36 to 44 h (100 rpm shaking, 27°C). All
subsequent steps were carried out at 4°C, except where noted. Cells were col-
lected by centrifugation at 500  g for 8 min, resuspended in 1:25 (vol/vol) of lysis
buffer (50 mM NaCl, 50 mM Tris [pH 8.0], 1.5% Triton X-100, 1 mM TCEP, and
mammalian protease inhibitor cocktail [Sigma] at 1:150 [vol/vol]), and lysed in a
100-ml Dounce homogenizer (15 strokes). The lysate was clarified by ultracen-
trifugation (Beckman Ti 50.2 rotor; 45,000 rpm, 184,000  g, 40 min), filtered
(0.45 m), and loaded at 2 ml/min onto a 10-ml StrepTactin Superflow affinity
column (IBA). The bound protein was washed with 50 ml of buffer (50 mM NaCl,
50 mM Tris [pH 8.0], 1 mM TCEP) and eluted with wash buffer supplemented
with 2.5 mM D-desthiobiotin. The eluate was loaded directly onto two 5-ml
HiTrap Q-Sepharose anion-exchange columns connected in series (GE Health-
care) and eluted with a NaCl gradient from 50 mM to 1 M over 200 ml of buffer
(50 mM Tris [pH 8.0], 1 mM TCEP). Purified TRIM5-21R eluted in two peaks
(see Fig. 1B). Fractions containing the early eluting peak were pooled, concen-
trated to 2 ml (Vivaspin concentrator; Sartorius), and loaded onto a 120-ml
Superose-6 gel filtration column. The later eluting protein fraction peak tended
to aggregate under high-ionic-strength conditions and was therefore loaded
directly onto a Superose-6 column without concentration (4-ml fractions). Gel
filtration chromatography was performed at 1 ml/min in 25 mM NaCl, 50 mM
Tris (pH 8.0), 1 mM TCEP. The gel filtration column was calibrated by using the
HMW standard gel filtration calibration kit (GE Healthcare), and the two
TRIM5-21R species eluted with apparent molecular masses of 232 kDa (dimer,
second anion exchange peak) and 70 kDa (monomer, first anion exchange peak).
The purified monomer could be concentrated to 10 mg/ml, whereas the dimer
tended to precipitate at concentrations above 3 mg/ml. Concentrated proteins
were stored at 4°C for short-term use but tended to precipitate when stored for
multiple days. Alternatively, proteins were flash frozen in liquid nitrogen and
retained CA-NC binding and autoubiquitylation activities when thawed.
(ii) Ubiquitin-related proteins. Recombinant E1 and E2 proteins were ex-
pressed in BL21-Codon Plus (DE3)-RIPL bacteria (Stratagene) grown in LB
media and purified as described previously (8). Briefly, human UbcH5c, UbcH6,
and UbcH7 were purified by cation-exchange chromatography (SP Sepharose)
and eluted with a 0 to 0.5 M NaCl gradient in 30 mM MES (morpholineethane-
VOL. 82, 2008 DIMERIC TRIM5-21R BINDS RETROVIRAL CAPSIDS 11683
sulfonic acid)–1 mM EDTA (pH 6.0). E2-rich fractions were pooled and purified
further by size exclusion chromatography in 25 mM sodium phosphate (pH
7.0)–150 mM NaCl. Wheat His6-Uba1 (E1) was purified by Ni2-affinity chro-
matography, followed by size exclusion chromatography. Ubiquitin was purified
as described previously (44).
Mass spectrometry. Monomeric and dimeric TRIM5-21R proteins were de-
salted for electrospray ionization mass spectrometry using a C18 Ziptip (Milli-
pore) and analyzed on a Quattro-II mass spectrometer (Micromass, Inc.). The
data were acquired with a cone voltage of 50 eV, a spray voltage of 2.8 kV, and
scanning from 800 to 1,400 m/z in 4 s. Spectra were combined, and the multiply
charged molecular ions were deconvoluted into a molecular-mass spectrum by
using MaxEnt software (Micromass, Inc.).
Liquid chromatography tandem mass spectrometry experiments were used to
examine posttranslational modifications of both TRIM5rh expressed in 293T
cells and TRIM5-21R expressed in SF-21 cells. TRIM5rh contained a C-termi-
nal HA tag (55) and was affinity purified from 293T cells by using -HA-
conjugated Sepharose matrices as described below for cross-linking experiments.
Dimeric TRIM5-21R was purified by anion-exchange chromatography, concen-
trated, and mixed with an equal volume of 2 sodium dodecyl sulfate (SDS)
loading buffer. In both cases, samples were boiled, separated by SDS–4 to
20%polyacrylamide gel electrophoresis (PAGE), and visualized using Coomassie
blue staining. Major bands corresponding to each TRIM5 protein, as well as
minor bands corresponding to higher-molecular-mass (modified) TRIM5 pro-
teins were excised, digested with TPCK (tolylsulfonyl phenylalanyl chloromethyl
ketone)-modified trypsin (Promega) and introduced by nanoLC (Eksigent, Inc.)
with nano-electrospray ionization (ThermoElectron Corp) into a LTQ-FT hybrid
mass spectrometer (ThermoElectron Corp). Peptide molecular masses were
measured by Fourier transform ion cyclotron resonance, and peptide sequencing
was performed by collision-induced dissociation in the linear ion trap of the
instrument. Protein identification and posttranslational modifications (phosphor-
ylation and ubiquitylation) of peptides in tryptic digests were determined by
using the MASCOT search engine (Matrix Science) and the NCBInr mammalian
taxonomy database using a significance threshold of P  0.05 and an ion score
cutoff value of 20 (Table 1).
Equilibrium sedimentation analyses. Equilibrium sedimentation of purified
TRIM5-21R proteins was performed using Optima XL-I and XL-A centrifuges
(Beckman) at protein subunit concentrations of 6.09, 3.05, and 1.53 M (mono-
mer) or 6.0, 3.0, and 1.5 M (dimer) in 50 mM Tris-HCl (pH 8.0)–50 mM
NaCl–1 mM -mercaptoethanol (monomer) or in 25 mM NaCl–50 mM Tris-HCl
(pH 8.0)–1 mM TCEP (dimer). Centrifugation (4°C) was performed at two
speeds: 14,000 and 18,000 rpm (monomer) and 14,000 and 16,000 rpm (dimer).
The resulting six data sets for each oligomeric species were globally fit to single
ideal species models with fixed or floating molecular masses using the nonlinear
least-squares algorithms in the Heteroanalysis software (9). Solvent density and
the partial specific volume of TRIM5-21R were calculated by using the program
SEDNTERP (version 1.09) (31).
Autoubiquitylation activity assays. TRIM5-21R-directed ubiquitylation assays
were carried out in 50-l reaction mixtures containing 1.0 M TRIM5-21R, 1.0
M concentrations of the specified E2 enzyme, 20 M ubiquitin, and 0.5 M
wheat Uba1. Reactions were incubated for 60 min with or without addition of 5
mM ATP–10 mM MgCl2, and reaction products were analyzed by SDS–7.5%
PAGE and Western blotting as described below.
Cross-linking reactions. (i) Cross-linking of recombinant TRIM5-21R pro-
teins. Pure recombinant TRIM5-21R proteins were dialyzed overnight into phos-
phate-buffered saline (PBS; 1 mM KH2PO4, 5.6 mM Na2HPO4, 154 mM NaCl)
plus 1 mM TCEP. Cross-linking reactions were then performed for 10 min at
25°C in 30-l reaction volumes at final protein concentrations of 0.5 M, along
with 0, 0.1, 0.5, or 1 mM fresh EGS [ethylene glycol-bis(succinimidyl succinate)]
cross-linker. Reactions were quenched by addition of 30 l of 0.1 M Tris-HCl
(pH 7.5), and samples were mixed with SDS loading buffer plus 1.2% -mer-
captoethanol, and analyzed by SDS–7.5% PAGE and Western blotting. For
reactions performed in the presence of mammalian cell lysate, recombinant
TRIM5-21R proteins in PBS plus 1 mM TCEP buffer were incubated in 30-l
reactions containing final concentrations of 50% clarified lysate prepared from
293T cells (see below), 0.25 M TRIM5-21R, and EGS at 0, 0.1, 0.5, or 1 mM (20
min, 25°C). Reactions were quenched by the addition of 30 l of 0.1 M Tris-HCl
(pH 7.5), diluted to 400 l with PBS plus 1 mM EDTA, and incubated with 30
l of StrepTactin Sepharose (IBA) at 4°C for 2 h. The matrix was washed four
times with PBS plus 0.5% NP-40 and resuspended in 30 l of SDS loading buffer
plus 1.2% -mercaptoethanol for Western blot analysis.
(ii) Cross-linking of TRIM proteins expressed in mammalian cells. For each
cross-linking series (four samples), a 10-cm plate of confluent 293T cells express-
ing OSF-tagged TRIM5-21R or HA-tagged TRIM5rh was lysed in 300 l of
PBS plus 0.5% NP-40 supplemented 1:150 with protease inhibitor cocktail
(Sigma) for 15 min on ice. Lysates were clarified by centrifugation at 16,100  g
for 30 min, and the resulting supernatant was diluted to a final volume of 1.7 ml
with PBS plus 1 mM EDTA. Then, 400-l aliquots of diluted lysate were incu-
bated with 0, 0.1, 0.5, or 1.0 mM EGS (20 min at 25°C). Reactions were quenched
by the addition of 400 l of 0.1 M Tris-HCl (pH 7.5), mixed with 30 l of
pre-equilibrated StrepTactin Sepharose (TRIM21-5R; IBA) or -HA-conju-
gated Sepharose (TRIM5rh; Sigma), and incubated for 2 h at 4°C. Matrices
were washed four times with PBS plus 0.5% NP-40 and resuspended in 30 l of
SDS loading buffer plus 1.2% -mercaptoethanol for Western blot analysis using
SDS–7.5% PAGE.
Western blotting. Proteins were separated by SDS-PAGE, transferred to
PVDF-FL membranes (Millipore) in Tris-glycine–10% methanol buffer, blocked
in 5% milk–Tris-buffered saline (20 min), and incubated with primary antibodies
diluted in 5% nonfat milk–Tris-buffered saline plus 0.1% Tween 20 (16 h, 4°C).
Blots were visualized by using an Odyssey infrared imaging system (Li-Cor, Inc.)
to detect Alexa 680-nm (Molecular Probes; 1:10,000) or IRDye 800-nm (Rock-
land; 1:10,000) secondary antibodies. The primary antibodies and dilutions used
were as follows: mouse anti-FLAG (Sigma) at 1:3,000 for OSF-TRIM5-21R (Fig.
1, 3 to 5, and 7), mouse anti-HA.11 (Sigma) at 1:1,000 for TRIM5-HA (Fig. 3),
rabbit anti-HIV-1 CA (UT415 made against purified NL4-3 CA protein and
affinity purified) at 1:15,000 (Fig. 5), and rabbit anti-EIAV CA (UT418 made
against purified EIAV CA protein and affinity-purified) at 1:5,000 (Fig. 7).
Restriction assays. (i) HIV-1 restriction assays. The HIV-1 vector pCMVR8.2,
which expresses a lacZ reporter, was packaged into vesicular stomatitis virus G-
pseudotyped HIV-1 as described previously (48a, 59a). For restriction assays, 3 
104 HeLa-M cells were seeded in 24-well plates and transfected (Lipofectamine
2000) 24 h later with 1 g of the control pcDNA-DEST40 vector or with vectors
expressing OSFT-TRIM5rh, OSFT-TRIM5-21R, OSFT-TRIM5-21RV1, or
OSFT-TRIM5-21RSPRY. Cells were incubated for 24 h, washed with media,
transduced for 24 h with various quantities of the HIV-1 vector, washed again, and
the percentage of infected cells was determined by assaying for lacZ expression at
48 h post infection. Equivalent expression levels of the different TRIM5 constructs
were verified by Western blotting.
(ii) EIAV restriction assay. To assay for restriction, 293T cells were transfected
in a 10-cm plate with the CeGFPW EIAV vector system as described below, and
infectivity was subsequently assayed as previously described (48). Briefly, dilu-
tions of vector preparations were added to target cells (HeLa or HeLa-
TRIM5rh, 2.0  105 cells/well, six-well plate) and incubated for 72 h at 37°C.
Transduction efficiencies were determined from the percentage of GFP-positive
cells measured by fluorescence-activated cell sorting.
EIAV core isolation. EIAV cores were prepared by using an adaptation of a
method described previously (30). Briefly, EIAV virions were produced by co-
transfection of 293T cells (16  10-cm plates) with an EIAV vector system.
Each 10-cm plate of cells was transfected (CalPhos mammalian transfection kit;
Clontech) with 8.1 g of pEV53 (EIAV structural proteins), 7.5 g of
pSIN6.1CeGFPW (packaged GFP expression vector), and 2.7 g of phCMV-
VSV-G (VSV-G envelope) (39, 69). After 36 h, the supernatants were removed,
pooled (four plates/pool), filtered (0.45-m pore size), and pelleted through a
4-ml 20% sucrose cushion in a Beckman SW-32Ti rotor (134,000  g, 2 h, 4°C).
Each set of pelleted virions was resuspended by gentle pipetting (4 h at 4°C) in
400 l of ST buffer (10 mM Tris-HCl [pH 7.4], 50 mM NaCl). Four 11.5-ml
sucrose gradients (30 and 70% [wt/vol] sucrose in ST buffer) were prepared in
14-by-89-mm tubes using a gradient mixer (Biocomp). The gradients were over-
laid with a 0.3-ml cushion of 15% sucrose containing 1% Triton X-100 and then
with a 0.3-ml barrier layer of 7.5% sucrose in ST buffer. Each tube of concen-











SF-21 TRIM5-21R 77* 54 7365
Ubiquitin 7† 79 138
293T TRIM5rh-HA 42* 47 2162
Ubiquitin 2 23 63
a *,Two nested TRIM5–21R phosphopeptides were identified: 81LREVKLSP
EEGQK93 and 83EVKLSPEEGQK93. †, One ubiquitylated ubiquitin peptide
was identified: 43LIFAGKQLEDGR54.
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trated EIAV particles was carefully layered on top of a gradient and centrifuged
in a Beckman SW-41 rotor (210,000  g, 16 h, 4°C). Twelve 1-ml fractions were
collected from the bottom of each tube, and fraction densities were measured by
using a digital refractometer (Leica), and EIAV CA was assayed by Western
blotting. Three 1-ml fractions of the correct density (1.22 to 1.26 g/ml) contained
intact EIAV core particles and were pooled, repelleted by centrifugation in a
Beckman SW-41 rotor (2,000  g, 2 h, 4°C), and resuspended in 40 l of ST
buffer for binding assays.
Capsid binding assays. Recombinant HIV-1 CA-NC was expressed and puri-
fied as described previously (21). Cylindrical and conical assemblies were created
by coincubating 10 M CA-NC and 2 M d(TG)50 oligonucleotide (15) in 1 ml
of assembly buffer (50 mM Tris-HCl [pH 8.0], 500 mM NaCl) for 16 h at 4°C.
Assembled complexes were enriched by centrifugation at 10,000 rpm in a mi-
crocentrifuge (9,000  g) for 5 min, and pelleted assemblies were resuspended
in 200 l of supernatant. TRIM5-21R proteins were used at final concentrations
of 5.0 M (for the experiments described in Fig. 5B and 6B comparing different
TRIM5-21R constructs), 0.5 or 0.15 M (0.3) (for the more stringent binding
assays described in Fig. 5C), or 0.36 M (for the EIAV core binding assays
described in Fig. 7B). TRIM5-21R proteins were mixed with 20 l of concen-
trated CA-NC particles (see the figure legends for quantities) or with purified
EIAV cores (100 ng, 20 nM CA) in reaction volumes of 200 l, with a final
buffer composition of 10 mM Tris, 2 mM KH2PO4, 11 mM Na2HPO4, and 280
mM NaCl (Fig. 5B), 308 mM NaCl (Fig. 5C, 1), 316 mM NaCl (Fig. 5C, 0.3),
or 250 mM NaCl (Fig. 7B). Reactions were incubated for 45 min at 25°C (CA-NC
binding assays) or 4°C (EIAV core assays) with gentle mixing at 10-min intervals.
Prior to centrifugation, a 10-l sample was removed and mixed with SDS loading
buffer (input). Binding reactions were layered onto a 4.2-ml cushion of 70%
(CA-NC) or 57% (EIAV cores) sucrose (wt/vol; sucrose-PBS plus 1 mM TCEP)
in 13-by-51-mm tubes and centrifuged in a Beckman SW-50.1 rotor (110,000 
g, 1 h, 4°C). Samples of the supernatant remaining above the sucrose cushion
were saved (supernatant), the sucrose cushions were removed by aspiration, and
the pellet was resuspended in 40 l of 1 SDS loading buffer. Input, supernatant,
and pellet samples were analyzed by Western blotting at concentrations in which
the supernatant samples corresponded to 1.25% (CA-NC) and 2% (EIAV cores)
of the total supernatant, and pellet samples corresponded to 80% of the total
pellet. Under these conditions, 2.5% of the input EIAV cores pelleted, and
1.6% (5.0 M input TRIM5-21R), 1.6% (0.5 M input TRIM5-21R), and
2.4% (0.15 M input TRIM5-21R) of the CA-NC assemblies pelleted.
Transmission electron microscopy analyses of TRIM-bound CA-NC tubes.
For transmission electron microscopy analyses, binding reactions containing 5-l
suspensions of CA-NC particles (prepared as described above) were incubated
with final TRIM5-21R concentrations of 20 to 50 M (15-l total volumes, 25°C,
45 min, with gentle mixing every 10 min). Carbon-coated grids were placed on
aliquots of each reaction mixture (7 l, 90 s), washed with 3 to 4 drops of 0.1 M
KCl, stained with 3 or 4 drops of 4% uranyl acetate, and air dried. Samples were
imaged on Hitachi 7100 and Philips Tecnai 12 transmission electron microscopes
at magnifications between 25,000 and 100,000. Each electron microscopic
analysis was repeated at least three times with proteins from at least three
separate purifications.
RESULTS
TRIM5-21R expression and purification. Wild-type rhesus
TRIM5 accumulates at low levels and tends to aggregate
when overexpressed in mammalian and insect cells (12; data
not shown). These properties have made it difficult to obtain
sufficient quantities of pure recombinant TRIM5 proteins
for biophysical and structural studies. Substitution of the
TRIM5rh RING domain with the RING domain of the ho-
mologous human TRIM21 protein (58% identity), however,
generates a fusion protein (designated TRIM5-21R) that has a
longer half-life and accumulates to higher levels in mammalian
cells than does wild-type TRIM5 (12). Importantly, TRIM5-
21R restricts HIV-1 replication, although its activity is slightly
reduced relative to wild-type TRIM5 (12; see also Fig. S1A in
the supplemental material). TRIM5-21R was therefore an at-
tractive candidate for large-scale expression in insect cells.
TRIM5-21R constructs with N-terminal OSF epitope tags
were expressed in SF-21 cells using baculoviral expression sys-
tems. TRIM5-21R expression was detectable in Western blots
of soluble lysates of infected SF-21 cells but not in control
lysates (Fig. 1A, upper panel, compare lanes 1 and 2). The
soluble TRIM5-21R protein was affinity purified on a Strep-
Tactin matrix, and elution with D-desthiobiotin yielded
TRIM5-21R as essentially the only protein detectable by either
Western blotting (upper panel, lane 3) or Coomassie blue
staining (lower panel). The protein was further purified by
anion-exchange chromatography, where it separated into two
distinct species, both of which corresponded to TRIM5-21R
(Fig. 1B, upper panel, and Fig. 1A, lanes 4 and 5). The ratios
of the two species varied between preparations, but it was
common for the late-eluting species to predominate, as shown
in Fig. 1B.
Gel filtration chromatography was used as a final step to
purify the two distinct TRIM5-21R species. The two species
again exhibited different chromatographic behavior, eluting
with apparent molecular weights of 232 kDa (late-eluting an-
ion-exchange peak) and 77 kDa (early-eluting anion-exchange
peak). The apparent size of the smaller protein suggested that
it was likely to be a TRIM5-21R monomer, whereas the ap-
parent size of the larger protein suggested that it was probably
either a trimer or a dimer with an extended Stokes radius.
Typical yields were 150 g (larger species) and 200 g (smaller
species) per liter of infected SF-21 cells.
The identities of the two purified recombinant TRIM5-21R
proteins were confirmed by electrospray mass spectrometric
(ESI/MS) analyses of the intact proteins, and by liquid chro-
matography tandem mass spectrometric analyses of tryptic di-
gests. The mass of the intact smaller species corresponded to a
TRIM5-21R protein that was missing the N-terminal methio-
nine and was acetylated at the N terminus (MWactual 	 62,518
g/mol, MWcalculated 	 62,520 g/mol), and the mass spectra
revealed no evidence for posttranslational modifications. In
contrast, the oligomeric species showed a protein of the same
mass (MWactual 	 62,517 g/mol), as well as a second protein
with a mass that corresponded to a singly phosphorylated pro-
tein (MWactual 	 62,596 g/mol, MWcalc 	 62,595; 30% of
protein). Peptide mapping experiments were therefore per-
formed on TRIM5-21R proteins produced in both SF-21 (in-
sect) and 293T (mammalian) cells. These studies identified a
single phosphoserine residue at position 87 within the L1
linker between the RING and B-box domains in TRIM5-21R
proteins isolated from both insect and human cells (Table 1,
TRIM5rh numbering). Given its location, this phosphoryla-
tion site could, in principle, modulate a postulated interaction
between the RING and adjacent L1 elements (24). Ubiquitin-
derived peptides were also detected in trypsin digests of puri-
fied TRIM5-21R expressed in both insect and mammalian
cells, indicating that the protein was also ubiquitylated at low
levels. Interestingly, ubiquitin peptides with Lys-48 isopeptide
linkages were also detected, indicating that TRIM5-21R could
be polyubiquitylated with Lys-48 chains.
In summary, we have developed methods that can be used to
express and purify up to milligram quantities of two different
TRIM5-21R oligomers, and the larger species can be phos-
phorylated and ubiquitylated in human and in insect cells.
Recombinant TRIM5-21R proteins are monomers and dimers.
Equilibrium sedimentation centrifugation experiments can
provide shape-independent measures of protein solution mass,
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and this approach was therefore used to determine the oligo-
meric state of each TRIM5-21R species. Sedimentation data
were collected at three different protein concentrations and
two rotor speeds, yielding a total of six data sets for each
TRIM5-21R species. These six data sets were globally fit to
single species models in which the molecular weight was al-
lowed to float and also to monomer, dimer, and trimer models
with fixed molecular weights. As illustrated in Fig. 2A, the
distribution of the smaller TRIM5-21R species fit a protein
with a predicted mass of 59,305 g/mol, which matched the mass
expected for a TRIM5-21R monomer (62,520 g/mol, Mobs/
Mcalc 	 0.95). The data for three initial concentrations of
TRIM5-21R centrifuged at 14,000 rpm are shown together
with the global fits (Fig. 2A, upper panel), and the small,
random residuals indicate that the data were satisfactorily fit by
a simple single species model (lower panels). Global fits to the
three data sets collected at 18,000 rpm were also satisfactory
(data not shown). Similarly, when fixed monomer, dimer, or
trimer molecular weights were used during the global fitting
procedure, the monomer model was clearly the best fit to the
data (see Fig. S2A in the supplemental material).
In contrast, equilibrium distributions of the larger TRIM5-
21R species indicated that this TRIM5-21R protein was a
dimer. As shown in Fig. 2B, data fit with a floating molecular
FIG. 1. TRIM5-21R expression and purification. (A) Western blot (upper, anti-FLAG) and Coomassie blue-stained SDS-PAGE gel (lower)
showing the stepwise purification of recombinant TRIM5-21R proteins. Lane 1, soluble lysate from control SF-21 cells; lane 2, lysate from SF-21
cells infected with baculovirus expressing TRIM5-21R; lane 3, StrepTactin affinity-purified TRIM5-21R; lanes 4 and 5, monomeric (M, early
eluting peak) and dimeric (D, late eluting peak) TRIM5-21R proteins purified by anion-exchange chromatography; lanes 6 and 7, monomeric (M,
late eluting peak) and dimeric (D, early eluting peak) TRIM5-21R proteins purified by gel filtration chromatography. (B) Anion-exchange (upper)
and gel filtration (lower) chromatographs showing the elution profiles of monomeric (M) and dimeric (D) TRIM5-21R proteins. Inset (upper
panel) shows a Coomassie blue-stained SDS-PAGE analysis of the designated fractions. Elution positions of control molecular mass standards are
shown below the gel filtration chromatograph for reference, and estimated molecular masses are given above the peaks of monomeric and dimeric
TRIM5-21R.
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weight gave an estimated mass of 123,825 g/mol, which
matched the molecular weight expected for a TRIM5-21R
dimer (125,040 g/mol, Mobs/Mmonomer 	 1.98), and the global
fits again exhibited small, random residuals (Fig. 2B and data
not shown). The dimer model was also clearly best when the
data were globally fit to fixed TRIM5-21R monomer, dimer, or
trimer models (see Fig. S2B in the supplemental material). We
therefore conclude that the smaller TRIM5-21R species is a
monomer and that the larger species is a dimer.
Recombinant TRIM5-21R dimers and mammalian TRIM5-
21R and TRIM5 proteins exhibit similar cross-linking pat-
terns. The observation that recombinant TRIM5-21R formed
monomers and dimers was somewhat surprising because pre-
vious studies had suggested that TRIM5 proteins might be
trimers (36). This conclusion was based upon the SDS-PAGE
electrophoretic mobilities of chemically cross-linked, mamma-
lian-expressed TRIM5 proteins, whose mobilities appeared
to correspond to trimers (150 kDa). To reconcile these ob-
servations, we tested whether chemically cross-linked TRIM5
dimers exhibited anomalously slow SDS-PAGE electro-
phoretic mobilities. Our first set of experiments examined
the mobilities of pure recombinant monomeric and dimeric
TRIM5-21R proteins cross-linked with EGS. The monomeric
protein was used as a control to ensure that protein and cross-
linker concentrations were sufficiently low to prevent nonspe-
cific intermolecular cross-linking of nonassociated proteins. As
shown in Fig. 3A, TRIM5-21R dimers formed intermolecular
cross-links efficiently, whereas TRIM5-21R monomers did not.
The major cross-linked species for the TRIM5-21R dimer mi-
grated at an apparent molecular mass of 160 kDa on a
SDS–7.5% PAGE gel, and a species migrating at 125 kDa
was also observed at trace levels. Thus, the major cross-linked
form of the TRIM5-21R dimer exhibits anomalously slow
SDS-PAGE mobility.
In a second set of experiments, we tested whether the oligo-
meric state or cross-linking properties of TRIM5 proteins
could be altered by cross-linking in crude lysates, by expression
in human versus insect cells, or by the non-native N-terminal
OSF tag or RING domain of the TRIM5-21R construct. As
shown in the first panel of Fig. 3B, the cross-linking pattern did
not change significantly when the pure recombinant TRIM5-
21R dimers were cross-linked either in a buffer solution or in
a soluble mammalian cell extract, indicating that TRIM5-21R
dimer does not appreciably cross-link with extract proteins
under these conditions (compare the first panel of Fig. 3B to
Fig. 3A). A very similar cross-linking pattern was also seen
when TRIM5-21R proteins were expressed in human 293T
cells and cross-linked directly in their soluble extracts (com-
pare Fig. 3B, second and third panels), although in this case
the minor, faster-migrating cross-linked species was more ev-
ident. This experiment indicates that TRIM5-21R forms sim-
ilar dimers when expressed in human or insect cells. Finally, we
examined the cross-linking of an authentic TRIM5 protein
expressed in 293T cells. Although the C-terminally HA-tagged
TRIM5 had a slightly lower molecular weight than TRIM5-
21R, the cross-linking pattern of the authentic TRIM5-HA
protein expressed in human 293T cells was again very similar to
those seen for the various TRIM5-21R proteins. Thus, TRIM5-21R
and TRIM5 proteins are predominantly dimeric when ex-
FIG. 2. Recombinant TRIM5-21R proteins are monomers and dimers. Equilibrium sedimentation distributions of purified monomeric (A) and
dimeric (B) TRIM5-21R proteins (upper panels), and residual differences between the data and the single species models (lower panels). The data
are shown for initial subunit protein concentrations of 6.09, 3.05, and 1.53 M (monomer), and 6.0, 3.0, and 1.5 M (dimer) at rotor speeds of
14,000 rpm. The data sets were also collected at 18,000 rpm (monomer) and 16,000 (dimer), and all of the data were globally fit to a single species
model in which the molecular weight was allowed to float during the refinement. The data points are shown in open symbols, and the best-fit curves
are shown as solid lines. Estimated molecular weights were as follows: TRIM5-21R monomer, 59,305 g/mol (MWmonomer 	 62,520 g/mol,
Mobs/Mcalc 	 0.95); and TRIM5-21R dimer, 123,825 g/mol (MWdimer 	 125,040 g/mol, Mobs/Mmonomer 	 1.98).
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pressed in human or insect cells, but the cross-linked dimers
exhibit anomalously slow electrophoretic mobilities.
Autoubiquitylation of recombinant TRIM5-21R proteins.
TRIM5 exhibits ubiquitin E3 ligase activity (63, 64), and a
recent study showed that a partially purified, recombinant
MBP-TRIM5 fusion protein could pair with the UbcH5b E2
enzyme and exhibit ubiquitin E3 ligase activity in vitro (64).
We also tested whether our purified TRIM5-21R proteins
were active for autoubiquitylation in vitro, using three different
pure E2 enzymes. As shown in Fig. 4, both monomeric and
dimeric TRIM5-21R proteins paired successfully with UbcH5c
and UbcH6, but not with UbcH7 in our in vitro autoubiquity-
lation assays. Ubiquitylation was particularly efficient in the
UbcH5 reactions, where most of the TRIM5-21R dimer was
modified with ubiquitin (compare lanes 8 and 9). Control re-
actions behaved as expected in that ubiquitylated products
were not observed in the absence of ATP (compare even and
odd lanes).
Interestingly, UbcH5 and UbcH6 produced dramatically dif-
ferent product distributions, with UbcH5 catalyzing polyubiq-
uitylation (or possibly multimonoubiquitylation) and UbcH6
catalyzing only monoubiquitylation of TRIM5-21R. These re-
sults demonstrate that the purified TRIM5-21R protein is an
active ubiquitin E3 ligase and are in good agreement with the
report of Yamauchi et al. (64), who found that MBP-TRIM5
was active with UbcH5B but not with UbcH7 (UbcH6 was not
tested). Our results are also consistent with the observations
that TRIM5, TRIM21, and TRIM5-21R can self-ubiquitylate
to form polyubiquitin chains in vivo, which can contain Lys-48
linkages (64; the present study). Finally, our experiments raise
the possibility that TRIM5 and TRIM21 may exhibit different
product distributions when paired with different E2 ubiquitin-
conjugating enzymes in vivo. Such behavior has been seen
previously for other RING and U-box E3 ligases (e.g., BRCA1
and CHIP, respectively) (8, 72) but remains to be confirmed
with in vivo studies of nonchimeric TRIM5 and TRIM21
proteins.
Recombinant TRIM5-21R proteins bind HIV-1 CA-NC as-
semblies. Although numerous studies have established that the
B30.2/SPRY domains of TRIM5 proteins dictate the speci-
ficity of retroviral capsid recognition (34, 38, 41, 54–56, 68),
direct binding of TRIM5 proteins to retroviral CA protein
assemblies has not yet been demonstrated. We therefore tested
whether pure recombinant TRIM5-21R proteins could bind
FIG. 3. Recombinant TRIM5-21R dimers and mammalian-expressed TRIM5-21R and TRIM5 proteins exhibit similar cross-linking patterns.
(A) Western blot (anti-FLAG) showing purified monomeric (M) and dimeric (D) proteins cross-linked with increasing concentrations of EGS
(lanes 3 to 8) or controls without EGS (lanes 1 and 2). (B) Western blots (anti-FLAG) showing purified recombinant TRIM5-21R dimer added
to 293T cell lysate and cross-linked in the presence of increasing concentrations of EGS (first panel); TRIM5-21R expressed in 293T cells,
cross-linked directly in the lysate, and concentrated by StrepTactin affinity purification (second panel); and TRIM5 expressed in 293T cells,
cross-linked directly in the lysate, and concentrated by -HA affinity purification (third panel). Lanes 1, 5, and 9 show controls in the absence of
EGS, and the asterisk denotes contaminating immunoglobulin G heavy chain eluted from the HA-Sepharose beads. Note that all of the samples
were run on the same gel, and migration positions can therefore be compared directly.
FIG. 4. TRIM5-21R proteins can be autoubiquitylated in vitro. Pu-
rified monomeric (lanes 1 to 6) and dimeric (lanes 7 to 12) TRIM5-
21R proteins were incubated with the wheat Uba1 E1 enzyme, ubiq-
uitin, and one of three ubiquitin E2-conjugating enzymes—UbcH5c,
UbcH6, or UbcH7—in the presence or absence of ATP. Reactions
were terminated after 60 min, and TRIM5-21R reaction products were
analyzed by Western blotting (-FLAG).
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the tubular and conical assemblies formed in vitro by pure
recombinant HIV-1 CA-NC proteins on DNA templates. Pre-
vious studies have shown that these CA-NC/DNA assemblies
form the same hexagonal surface lattices as authentic HIV-1
capsids and should therefore present native-like capsid sur-
faces for TRIM5-21R recognition. Our binding studies took
advantage of the observation that CA-NC/DNA assemblies
can be separated from free proteins by centrifugation through
sucrose cushions (56). TRIM5-21R proteins therefore re-
mained in the supernatants above the cushion, unless they
bound and copelleted with the CA-NC/DNA assemblies.
Our studies used both monomeric and dimeric wild-type
TRIM5-21R proteins, as well as two mutant TRIM5-21R pro-
teins used as specificity controls (Fig. 5A). The first specificity
control (denoted TRIM5-21RV1) lacked 13 residues from
the middle of the V1 recognition loop of the SPRY domain
(10). This loop is required for efficient HIV-1 capsid binding
and restriction, although the TRIM5-21RV1 protein does
retain modest residual HIV-1 restriction activity (10; see Fig.
S1A in the supplemental material). The recombinant TRIM5-
21RV1 protein behaved like wild-type TRIM5-21R in that it
formed both monomers and dimers, and the purified TRIM5-
21RV1 dimer was used in our studies. The second specificity
control (denoted TRIM5-21RSPRY) lacked the entire
SPRY domain and the preceding L2 linker. This control was
used because TRIM5 constructs lacking SPRY domains can-
not bind HIV-1 capsid in extracts or restrict HIV-1 replication
in vivo (56). This construct differed from wild-type TRIM5-
21R in that it was exclusively monomeric (data not shown), and
the purified monomer was therefore used in our studies.
As shown in Fig. 5B, CA-NC/DNA proteins formed a mix-
ture of assembled tubes and cones, which pelleted to the bot-
tom of the sucrose cushion, and disassembled proteins, which
remained in the supernatant (lanes 5 to 8). As expected, all
FIG. 5. TRIM5-21R binds CA-NC assemblies. (A) Schematic summary (above) and SDS-PAGE/Coomassie blue analyses (below) of purified
full-length dimeric TRIM5-21R (lane 3, denoted WT), a dimeric TRIM5-21R construct missing part of the V1 loop (lane 2, denoted V1), and
a monomeric TRIM5-21R construct missing the entire SPRY domain (lane 1, denoted SPRY). (B) TRIM5-21R protein binding to CA-NC/DNA
assemblies. Monomeric (M) or dimeric (D) TRIM5-21R (WT, lanes 3 and 4 and lanes 7 and 8), TRIM5-21RV1 (V1, lanes 2 and 6), or
TRIM5-21RSPRY (SPRY, lanes 1 and 5) proteins were incubated alone (lanes 1 to 4) or with CA-NC/DNA assemblies (lanes 5 to 8) and then
centrifuged through a 70% sucrose cushion to separate CA-NC assemblies and bound proteins (pellet) from unbound and lower-molecular-weight
proteins (supernatant). Western blots show the distribution of TRIM (-FLAG, first, third, and fifth panels) and CA-NC (-CA, second, fourth,
and sixth panels). Note that CA-NC assemblies bound full-length TRIM5-21R constructs better than either TRIM5-21RV1 or TRIM5-
21RSPRY. Ratios of bound CA-NC and TRIM5-21R proteins were obtained by combining known input protein concentrations, quantification
of bound CA-NC levels using a standard curve of known CA-NC protein concentrations, and quantification of Western blot band intensities.
Estimated bound ratios were as follows: CA-NC/TRIM5-21R dimer 	 1.1, CA-NC/TRIM5-21R monomer 	 0.8, and CA-NC/TRIM5-21RV 	
0.18. (C) CA-NC/DNA assemblies bind better to dimeric TRIM5-21R proteins than to monomeric proteins under stringent conditions. Monomeric
(lanes 2, 4, and 6) or dimeric (lanes 1, 3, and 5) proteins were incubated alone (lanes 1 and 2) or with CA-NC/DNA assemblies (lanes 3 to 6) and
then centrifuged through a 70% sucrose cushion to separate CA-NC assemblies and bound proteins (pellet) from unbound and lower molecular
weight proteins (supernatant). Western blots show the distribution of TRIM5-21R (-FLAG, TRIM panels) and CA-NC (-CA, CA-NC panels).
The concentrations of TRIM5-21R proteins in lanes 5 and 6 were 3.33-fold higher than in lanes 3 and 4, and all binding assays were performed
at lower protein concentrations than those shown in part (B) (see Materials and Methods). Note that under these conditions, CA-NC assemblies
bound dimeric TRIM5-21R better than monomeric TRIM5-21R. The estimated ratios of bound proteins were as follows: CA-NC/TRIM5-21R
dimer (0.15 M input) 	 0.025; CA-NC/TRIM5-21R monomer (0.15 M input) 	 0.01, CA-NC/TRIM5-21R dimer (0.5 M input) 	 0.068; and
CA-NC/TRIM5-21R monomer (0.5 M input) 	 0.028.
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TRIM5-21R proteins remained exclusively in the supernatant
in the absence of CA-NC/DNA assemblies (lanes 1 to 4, com-
pare panels 3 and 5). In the presence of CA-NC/DNA as-
semblies, however, both monomeric and dimeric wild-type
TRIM5-21R proteins partitioned between the supernatant and
pellet fractions, indicating that both TRIM5-21R proteins
could bind CA-NC/DNA assemblies (compare lanes 7 and 8 to
lanes 3 and 4 in the sixth panel). The TRIM5-21RV1 protein
also bound detectably to CA-NC/DNA assemblies (compare
lane 6 to lane 3), but at much lower levels than either of the
two wild-type TRIM5-21R proteins (compare lane 6 to lanes 7
and 8). A deletion in the SPRY domain V1 loop therefore
reduced, but did not entirely eliminate, CA-NC/DNA binding.
The TRIM5-21RSPRY protein did not bind CA-NC/DNA
assemblies detectably in this assay, indicating that the SPRY
domain was required for CA-NC/DNA binding (compare lane
5 to lanes 7 and 8). These experiments demonstrate that pure
recombinant TRIM5-21R proteins bind directly to CA-NC/
DNA assemblies and show that efficient binding requires the
SPRY domain and its V1 loop.
Although our binding experiments were not performed un-
der equilibrium conditions, we have nevertheless estimated the
concentrations and stoichiometries of the binding reaction
components in an initial effort to define the parameters that
govern the TRIM5-CA interaction. CA-NC tubes and cones
can assemble and disassemble reversibly, and we therefore
estimated the concentration of CA-NC protein in the pellet-
able assemblies by quantifying Western blot band intensities
and comparing them to a standard curve of known CA-NC
concentrations. Analyzed in this fashion, the pelletable CA-NC
protein in each experiment shown in Fig. 5B corresponded to
11 pmol (corresponding to an initial concentration of 55 nM).
The initial concentration of TRIM5-21R subunits in each re-
action mixture was 5 M, and the quantity of pelleted TRIM5-
21R dimer corresponded to 12 pmol of protein. Thus, in this
experiment, the binding reaction was performed with substan-
tial excess of TRIM5-21R dimer over assembled CA-NC pro-
tein (100-fold), and under these conditions the ratio of
bound TRIM5-21 to CA-NC was approximately 1:1. The
TRIM5-21RV1 protein bound less well in this experiment, at
a TRIM5-21V1/CA-NC ratio of 0.18:1. Although these esti-
mated values neglect several potential complications, including
possible incomplete CA-NC tube pelleting efficiency and dis-
sociation of CA-NC assemblies during the assay, the data nev-
ertheless imply that TRIM5-21R can bind assembled CA-NC
lattices at nearly stoichiometric levels.
CA-NC/DNA assemblies bind TRIM5-21R dimers more ef-
ficiently than monomers. TRIM5 protein oligomerization has
been shown to enhance retroviral capsid binding owing to
avidity effects (27), and it was therefore surprising that CA-
NC/DNA assemblies bound equivalent levels of TRIM5-21R
monomers and dimers in the previous assay. We therefore
tested whether more stringent binding conditions might reveal
differential CA-NC binding of TRIM5-21R monomers and
dimers. The stringency was increased by reducing the TRIM5-
21R concentration, and under these conditions CA-NC/DNA
assemblies bound TRIM5-21R dimers better than monomers.
This effect is illustrated in Fig. 5C, which shows that TRIM5-
21R dimers bound better at two different initial TRIM5-21R
concentrations (0.5 and 0.15 M, compare lanes 3 and 4 to
lanes 5 and 6 in the bottom panel). Under these more stringent
conditions, the quantity of pelletable CA-NC protein did not
change, but the ratios of pelletable CA-NC to bound TRIM5-
21R proteins were substantially lower, demonstrating that the
binding conditions were indeed more stringent (see the caption
to Fig. 5C). These data suggest that although TRIM5-21R
monomers and dimers can both bind CA-NC/DNA assemblies,
TRIM5-21R dimerization enhances the efficiency of binding
under more stringent conditions, in agreement with the obser-
vation that disruption of the coiled-coil oligomerization motif
of TRIM5 inhibits restriction (27).
Electron microscopic analyses of TRIM5-21R-decorated
CA-NC tubes. The effects of TRIM5-21R binding to CA-NC
tubes were visualized by using transmission electron micros-
copy of negatively stained CA-NC/DNA assemblies incubated
with a 10- to 50-fold excess of TRIM5-21R prior to imaging. As
shown in Fig. 6, TRIM5-21R binding did not dramatically alter
the appearance of CA-NC/DNA tubes, but two effects were
evident. First, CA-NC/DNA tubes incubated with excess
TRIM5-21R consistently exhibited increased exterior stain
deposition compared to tubes incubated with control TRIM5-
21RV1 or TRIM5-21RSPRY proteins. The simplest expla-
nation for this effect is that it reflects formation of TRIM5-21R
coats on the CA-NC/DNA tube exteriors. This effect was
sometimes subtle and difficult to discern, but in extreme cases
resulted in a thick, dark irregular coat on tube exteriors, as
though the TRIM5-21R were aggregating about the tube (Fig.
6, panel 8). Second, CA-NC/DNA tubes decorated with
TRIM5-21R frequently appeared more broken and irregular
than their counterparts incubated with control TRIM5-
21RV1 or TRIM5-21RSPRY proteins (tube breaks are
highlighted by arrows in Fig. 6, panels 5 to 8). This observation
suggests that high levels of TRIM5-21R destabilized the tubes
and increased their fragmentation, although the effect was
modest, and most tubes remained intact. Overall, our electron
microscopic data indicate that TRIM5-21R can coat and de-
stabilize CA-NC/DNA assemblies, but both effects were subtle.
Higher-resolution cryo-electron microscopic analyses will be
required to determine the density and location of TRIM5-21
binding sites on the CA-NC/DNA assemblies.
EIAV core binding assays. Retroviral cores are the actual
targets of TRIM5 restriction, and we therefore tested
whether TRIM5-21R could bind authentic, purified core par-
ticles. Cores isolated from EIAV vectors were used in these
experiments because TRIM5rh restricts EIAV (10, 23, 71; see
Fig. S1B in the supplemental material) and because we are
able to purify cores from membrane-stripped EIAV virions
more reproducibly and in higher yields than HIV-1 cores.
EIAV cores were membrane stripped with a brief Triton X-100
detergent treatment (30) and then purified on a sucrose gra-
dient where they concentrated at the expected density of 1.24
g/ml (Fig. 7A).
Purified EIAV cores were incubated with a 16-fold excess
of pure recombinant TRIM5-21R or control V1 or SPRY
variants. As in the CA-NC/DNA binding assay, high-molecu-
lar-weight EIAV cores were pelleted by centrifugation through
a sucrose cushion (Fig. 7B, lanes 4 to 6 in the sixth panel).
Wild-type dimeric TRIM5-21R protein bound and copelleted
with the EIAV cores but did not pellet in the absence of cores
(compare lanes 3 and 6, fifth panel). In contrast, much lower
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levels of the control TRIM5-21R V1 protein copelleted with
the EIAV cores (compare lanes 5 and 6), and no detectable
TRIM5-21R SPRY protein copelleted with the cores (com-
pare lanes 4 and 6). We therefore conclude that TRIM5-21R
binds and copellets with authentic EIAV core particles and
that this interaction is specific because the wild-type TRIM5-
21R protein binds much better than control proteins lacking
part of the V1 loop or the entire SPRY domain.
FIG. 6. Electron microscopic images of CA-NC assemblies incubated
with full-length TRIM5-21R or deletion mutants. Negatively stained,
transmission electron microscopic images of CA-NC assemblies incu-
bated with monomeric TRIM5-21RSPRY (panels 1 and 2), dimeric
TRIM5-21RV1 (panels 3 and 4), or full-length dimeric TRIM5-21R
(panels 5 to 8). Note that CA-NC/DNA assemblies incubated with
TRIM5-21R show enhanced exterior staining and more frequent breaks
(arrows) compared to the TRIM5-21RV1 or TRIM5-21RSPRY con-
trols. TRIM5-21R-induced breaks were quantified by scoring randomly
selected electron microscopic images of CA-NC/DNA tubes for the pres-
ence of discontinuities (see arrows), with the following results: TRIM5-
21RSPRY-treated tubes (0% broken, 0 total breaks, n 	 26 tubes),
TRIM5-21RV1-treated tubes (4% broken, 2 total breaks, n 	 50), and
TRIM5-21R-treated tubes (42% broken, 55 total breaks, n 	 50).
FIG. 7. TRIM5-21R binds EIAV cores. (A) Sucrose gradient pu-
rification of membrane-stripped cores produced by an EIAV vector.
The Western blot (-CA) shows the distribution of EIAV CA protein
across a sucrose density gradient (with fraction densities shown). The
CA distribution is quantified below, and the CA protein in fractions 10
to 12 corresponds to core particles. (B) TRIM5-21R protein binding to
purified EIAV cores. Dimeric TRIM5-21R (WT, lanes 3 and 6), di-
meric TRIM5-21RV1 (V1, lanes 2 and 5), or monomeric TRIM5-
21RSPRY (SPRY, lanes 1 and 4) proteins were incubated alone
(lanes 1 to 3) or with purified EIAV cores (lanes 4 to 6) and then
centrifuged through a 57% sucrose cushion to separate EIAV cores
and bound proteins (pellet) from unbound and lower-molecular-
weight proteins (supernatant). Western blots show the distribution of
TRIM (-FLAG, TRIM panels) and EIAV CA (-CA, CA panels).
Note that the pelleted EIAV cores bound full-length TRIM5-21R
better than either TRIM5-21RV1 or TRIM5-21RSPRY.
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DISCUSSION
We have described the expression, purification, and charac-
terization of TRIM5-21R, which represents the first study of a
pure recombinant TRIM5 protein capable of restricting
HIV-1 replication. Our experiments provide direct experimen-
tal support for the importance of both TRIM5 protein oligo-
merization and the B30.2/SPRY domain in retroviral capsid
recognition. Specifically, we found that deletion of the SPRY
domain eliminates binding to both HIV-1 CA-NC assemblies
and EIAV cores, that a deletion in the V1 loop reduces binding
significantly, and that TRIM5-21R dimerization enhances
binding to HIV-1 CA-NC assemblies under stringent binding
conditions. These in vitro binding activities correlate well with
restriction activities in vivo, indicating that our in vitro exper-
iments accurately recapitulate interactions between capsids
and TRIM5 proteins during retroviral restriction.
Our experiments indicate that restricting TRIM5 proteins,
including TRIM5 itself, are dimers. Previous studies had
established that TRIM5 proteins oligomerize and that the
oligomeric state might be trimeric (27, 36). We now show,
however, that TRIM5-21R forms dimers but that chemically
cross-linked TRIM5-21R dimers exhibit anomalously slow
electrophoretic mobility, causing them to appear trimeric.
Cross-linked TRIM5 proteins expressed in mammalian
cells exhibit very similar mobilities, implying that authentic
TRIM5 proteins are also dimeric. It will be of interest to
determine whether other members of the TRIM protein family
are also dimers. In this regard, we note that others have re-
ported that the related TRIM21 protein forms trimers (45).
This conclusion was again based upon the electrophoretic mo-
bility of chemically cross-linked TRIM21 proteins, however,
which may be subject to the same uncertainties as cross-linked
TRIM5 proteins. Moreover, another group has reported that
the TRIM21/SS-A/Ro52 protein may instead be dimeric, based
on its gel filtration mobility (59), and two groups have reported
that the isolated coiled-coil region of TRIM21 forms dimers
rather than trimers (27, 40). We therefore speculate that
dimerization may be a common property of many members of
the tripartite motif protein family. If so, there are several
intriguing similarities between TRIM proteins and immuno-
globulin G proteins, since both types of protein can dimerize to
display a pair of terminal immunoglobulin-like domains that
can recognize antigens, including repeating motifs on viral
capsid surfaces.
Once formed, TRIM5-21R dimers are stable and can be
purified without appreciable dissociation. Similarly, we saw no
evidence of monomer accumulation in equilibrium distribu-
tions of TRIM5-21R dimers across a range of micromolar
concentrations, again indicating that assembled TRIM5-21R
dimers are highly stable (or kinetically inert). Nevertheless,
monomeric TRIM5-21R proteins were produced in our bacu-
loviral expression system. These TRIM5-21R monomers did
not exhibit a propensity to dimerize, suggesting that they may
be kinetically “trapped,” perhaps owing to misfolding of the
coiled-coil motif. Not surprisingly, a TRIM5-21R construct
missing the SPRY domain and preceding L2 linker was exclu-
sively monomeric, a finding consistent with previous experi-
ments showing that the TRIM5 L2 region is required for
oligomerization (40).
SPRY domains of TRIM proteins, presumably including
TRIM5, adopt immunoglobulin-like folds consisting of two
antiparallel -sheets. The ligand binding surface is located at
one end of the -sandwich and is composed of six extended
loops and two pockets (25, 61). The loops, which are hyper-
variable in both amino acid composition and length, share
homology with the complementarity-determining region loops
of immunoglobulins and account for the species specificity of
restriction. In particular, the variable region 1 loop of
TRIM5rh is a critical determinant of capsid binding and an-
tiviral activity, and a deletion within the V1 loop also reduced
capsid recognition by TRIM5-21R in our in vitro binding as-
says. Our results are therefore in good agreement with the
prevailing model that retroviral capsid recognition is mediated
by the variable loops of the SPRY domain of TRIM5 (34, 54,
68). Furthermore, our experiments demonstrate that this in-
teraction is direct and can be highly efficient. Indeed, under
some conditions we observed essentially stoichiometric binding
of TRIM5-21R to CA-NC assemblies. Electron microscopic
images of CA-NC tubes decorated with TRIM5-21R proteins
also suggest that TRIM5-21R can “coat” the CA-NC surface,
although higher-resolution studies will be necessary to confirm
and extend this finding.
TRIM5 restriction represents a very intriguing problem in
molecular recognition because specific TRIM5 alleles are
able to recognize a remarkable variety of different retroviral
capsids, despite their substantial variation in amino acid se-
quence and surface topology. This attribute is exemplified by
TRIM5rh, which is able to recognize both EIAV and HIV-1
capsids even though the HIV-1 and EIAV CA proteins share
only 25% sequence identity. Retroviral capsids do share a
common organization, however, since all capsids are assem-
bled on a hexagonal surface lattice composed of CA hexamers.
It is therefore likely that both reading heads of the dimeric
TRIM5 protein engage similar sites on the capsid surface,
and this is most easily accomplished by binding across a local
twofold symmetry axis on the capsid lattice (although asym-
metric binding is also a formal possibility). Hexagonal HIV-1
CA arrays exhibit two distinct types of local twofold symmetry,
one of which is colinear with the local sixfold axes and the
other of which connects adjacent hexamers. These two sites
have different subunit orientations and spacing, and it is there-
fore likely that only one of these sites is the preferred TRIM5
binding site.
In solution, HIV-1 CA forms dimers that correspond to the
twofold symmetric interactions between adjacent hexamers in
the assembled hexagonal lattice. Expression of HIV-1 CA
alone does not abrogate restriction, however, indicating that
the CA dimer alone probably does not create a high-affinity
TRIM5 binding site (14, 16, 51, 52). It is possible that CA
alone cannot abrogate restriction because the CA solution
dimer is not the preferred TRIM5 binding site or because this
CA dimer is weak and/or inherently flexible. However, an
interesting alternative is that isolated SPRY domains, and even
isolated TRIM5 dimers, may have weak intrinsic capsid bind-
ing energies and that high-affinity binding is achieved through
the cooperative formation of even higher-order TRIM5 as-
semblies. This model would be consistent with the observation
that TRIM5 proteins are highly susceptible to aggregation or
assembly in vitro and in vivo. Indeed, fluorescence images
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indicate that at least in some cases, large numbers of TRIM5
proteins can assemble on HIV-1 capsids in vivo (6). This model
could also help explain how individual TRIM5 alleles can bind
such a variety of different retroviral capsid surfaces because
direct TRIM5-CA interfaces would not need to form a large
number of favorable interactions but rather could utilize just a
few specific interactions and then be stabilized by the cooper-
ative formation of multiple TRIM5-CA and TRIM5-
TRIM5 interfaces. In contrast, isolated TRIM-Cyp proteins,
in which a cyclophilin A domain replaces the SPRY domain,
may bind specific retroviral capsids with higher affinities be-
cause the cyclophilin A domain can make specific interactions
with individual HIV-1 CA subunits (18, 70). This “high-affin-
ity” recognition mechanism could explain why the upstream
RING and B-box domains play less important roles in TRIM-
Cyp restriction activity (10, 13, 65, 66) but may come at the cost
of reducing the ability of TRIM-Cyp restriction factors to rec-
ognize as broad a variety of different retroviral capsids as
canonical TRIM5 alleles.
Our electron microscopic analyses also indicated that high-
level TRIM5-21R binding destabilizes the CA-NC lattice to
some degree because TRIM5-21R induced many more breaks
in CA-NC/DNA tubes than did nonbinding control TRIM5-
21R constructs. Destabilization of the CA-NC lattice could
reflect steric hindrance upon saturation binding of TRIM5-
21R and/or mismatches in the symmetry or spacing between
the CA-NC lattice and putative higher-order TRIM5-21R as-
semblies. We emphasize, however, that the capsid destabiliza-
tion induced by TRIM5-21R binding was a relatively minor
effect because most CA-NC assemblies remained largely in-
tact, even in the presence of a large excess of TRIM5-21R.
Similarly, EIAV cores remained pelletable in the presence of
excess TRIM5-21R. Thus, the dramatic destabilization of ret-
roviral capsids observed under restrictive conditions in vivo
does not appear to be a direct consequence of TRIM5 bind-
ing. Rather, it appears that capsid recognition by TRIM5 and
subsequent destabilization/restriction are largely separable
events. This idea is consistent with a series of other observa-
tions, including the fact that mutations in the B-box region of
TRIM5 can abrogate restriction without apparently affecting
capsid recognition (11), and that capsid destabilization is ab-
rogated upon inhibition of the proteasome (6, 10).
In summary, our biochemical and biophysical studies have
established that purified recombinant TRIM5-21R forms sta-
ble dimers that can bind specifically to higher-order HIV-1
CA-NC assemblies and to authentic EIAV core particles. It
will be important to ascertain precisely how TRIM5 binds the
capsid lattice and to determine the minimal CA assembly re-
quired for high-affinity binding, and we anticipate that the
availability of recombinant TRIM5-21R protein will facilitate
such studies.
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